IL114049A - Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel - Google Patents

Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel

Info

Publication number
IL114049A
IL114049A IL11404995A IL11404995A IL114049A IL 114049 A IL114049 A IL 114049A IL 11404995 A IL11404995 A IL 11404995A IL 11404995 A IL11404995 A IL 11404995A IL 114049 A IL114049 A IL 114049A
Authority
IL
Israel
Prior art keywords
active agent
gel
acne
psoriasis
release
Prior art date
Application number
IL11404995A
Other languages
English (en)
Other versions
IL114049A0 (en
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to IL12235995A priority Critical patent/IL122359A/xx
Priority to IL12235895A priority patent/IL122358A/xx
Publication of IL114049A0 publication Critical patent/IL114049A0/xx
Publication of IL114049A publication Critical patent/IL114049A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11404995A 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel IL114049A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12235995A IL122359A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation
IL12235895A IL122358A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07

Publications (2)

Publication Number Publication Date
IL114049A0 IL114049A0 (en) 1995-10-31
IL114049A true IL114049A (en) 2000-08-31

Family

ID=22966815

Family Applications (3)

Application Number Title Priority Date Filing Date
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel
IL12235895A IL122358A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility
IL12235995A IL122359A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL12235895A IL122358A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility
IL12235995A IL122359A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation

Country Status (13)

Country Link
US (2) US5914334A (de)
EP (2) EP0764032B1 (de)
AT (2) ATE336263T1 (de)
AU (1) AU693905B2 (de)
CA (1) CA2191773C (de)
DE (2) DE69526344T2 (de)
DK (1) DK1147778T3 (de)
ES (2) ES2269296T3 (de)
IL (3) IL114049A (de)
PT (1) PT1147778E (de)
TW (1) TW379143B (de)
WO (1) WO1995033489A1 (de)
ZA (1) ZA954599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (it) * 1996-10-17 1998-09-23 Achille Sandoli Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.
EP0969847A1 (de) * 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene und carticosteroid enthaltende zusammensetzungen zur behandlung von psoriasis
JP2002504121A (ja) * 1997-06-11 2002-02-05 アラーガン・セイルズ・インコーポレイテッド タザロテンおよびｕｖｂ光線療法による乾癬の処置
WO1999049841A1 (en) * 1998-03-30 1999-10-07 The Procter & Gamble Company Skin care compositions
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
AU5378201A (en) * 2000-04-26 2001-11-07 Watson Pharmaceuticals Inc Minimizing adverse experience associated with oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
KR20050085740A (ko) * 2002-12-17 2005-08-29 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. 염기를 이용하여 용매 내에서 가용화된 레티노이드를화학적으로 안정화시키는 방법
FR2848451B1 (fr) * 2002-12-17 2007-01-12 Galderma Res & Dev Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
JP2008540514A (ja) * 2005-05-10 2008-11-20 ダーミプソル リミテッド 過剰増殖表皮疾患の治療用組成物及び方法
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
BRPI0709674A2 (pt) 2006-03-31 2011-12-06 Stiefel Research Australia Pty Ltd. gel de suspensão espumante
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
PL2544532T3 (pl) 2010-03-12 2017-08-31 Monsanto Technology Llc Agrochemiczne kompozycje żelowe
EP2624817A1 (de) * 2010-10-08 2013-08-14 Helperby Therapeutics Limited Neuartige zusammensetzung
MX2016005645A (es) 2013-10-31 2017-01-05 Sun Pharmaceutical Ind Ltd Composicion farmaceutica topica de acitretina.
US11311529B2 (en) * 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR102976809B1 (ko) * 2021-09-15 2026-06-23 (주)샤페론 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
DE69029804T2 (de) * 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
JP2002504121A (ja) * 1997-06-11 2002-02-05 アラーガン・セイルズ・インコーポレイテッド タザロテンおよびｕｖｂ光線療法による乾癬の処置
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
DE69526344T2 (de) 2002-11-07
CA2191773C (en) 2004-08-10
DK1147778T3 (da) 2006-12-18
EP1147778B1 (de) 2006-08-16
EP0764032B1 (de) 2002-04-10
DE69535184D1 (de) 2006-09-28
ZA954599B (en) 1996-01-26
DE69526344D1 (de) 2002-05-16
EP0764032A1 (de) 1997-03-26
TW379143B (en) 2000-01-11
AU693905B2 (en) 1998-07-09
ES2269296T3 (es) 2007-04-01
IL122359A (en) 2001-08-26
IL114049A0 (en) 1995-10-31
US5914334A (en) 1999-06-22
DE69535184T2 (de) 2007-08-23
ATE336263T1 (de) 2006-09-15
US6258830B1 (en) 2001-07-10
WO1995033489A1 (en) 1995-12-14
IL122358A (en) 2001-01-28
CA2191773A1 (en) 1995-12-14
ES2173958T3 (es) 2002-11-01
PT1147778E (pt) 2006-12-29
EP1147778A1 (de) 2001-10-24
ATE215836T1 (de) 2002-04-15
AU2821895A (en) 1996-01-04

Similar Documents

Publication Publication Date Title
IL122358A (en) Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility
IN1997DE00284A (de)
WO1996012498A3 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
CA2262870A1 (en) Liposome-based topical vitamin d formulation
IL105413A0 (en) Aqueous gel retinoid compositions
NZ503340A (en) Treatment for hairy hoof warts (papiliomatous digital dermatitis, or PDD)
AU674142B2 (en) Use of cosmetic composition
KR970706038A (ko) 모발 제거 방법(method of hair removal)
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
CA2291144A1 (en) Topical treatment of psoriasis using neutralizing antibodies to il-8
ZA904971B (en) Stable,cosmetically acceptable topical gel formulation and method of treatment for acne
AU3202595A (en) 1,2-substituted imidazolyl compounds for the treatment of inflammation
WO1999008650A3 (en) Use of ascorbic acid in permanent waving and hair coloring compositions
EP0766960A4 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
BR9607128A (pt) Emulsão de aplicação tópica aperfeiçoada para carregar ácido ascórbico e ingredientes ativos solúveis em água e cápsula mole de getatina
PH31607A (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatosis.
CA2339384A1 (en) Improved method for targeted topical treatment of disease
NZ506681A (en) Disinfecting composition
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ATE234071T1 (de) Gegen akne und entzündete comedonen wirksame wirkstoffkombinationen
CA2231118A1 (en) Pharmaceutical preparation containing nimesulide for topical use
AU2415099A (en) Active substance combination
ATE168004T1 (de) Juckreizstillendes mittel
EP0685230A4 (de) Stabile dermatologische zubereitungen, die mycohenolsäure enthalten.
IL136342A0 (en) Formulation for topical treatment of skin infections

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired